CO-AMOXICLAV PFIZER

Main information

  • Trade name:
  • CO-AMOXICLAV PFIZER
  • Dosage:
  • 875/ 125 Milligram
  • Pharmaceutical form:
  • Film Coated Tablet
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • CO-AMOXICLAV PFIZER
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PA0822/085/002
  • Authorization date:
  • 26-08-2011
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

Co-amoxiclavPfizer875mg/125mgFilm-coatedTablets

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachfilm-coatedtabletcontainsamoxicillintrihydrateequivalentto875mgamoxicillinwithpotassiumclavulanate

equivalentto125mgclavulanicacid.

Forafulllistofexcipients,seesection6.1.

3PHARMACEUTICALFORM

Filmcoatedtablet.

Co-amoxiclavPfizer875mg/125mgtabletsarewhite,capsuleshaped,film-coatedtabletsinscribedwith‘A’onone

sideandwithascorelineinbetween‘6’and‘5’ontheotherside.

Thescorelineisonlytofacilitatebreakingforeaseofswallowingandnottodivideintoequaldoses.

4CLINICALPARTICULARS

4.1TherapeuticIndications

Co-amoxiclavPfizerisindicatedforthetreatmentofthefollowinginfectionsinadultsandchildren(seesections4.2,

4.4and5.1):

Acutebacterialsinusitis(adequatelydiagnosed)

Acuteotitismedia

Acuteexacerbationsofchronicbronchitis(adequatelydiagnosed)

Communityacquiredpneumonia

Cystitis

Pyelonephritis

Skinandsofttissueinfectionsinparticularcellulitis,animalbites,severedentalabcesswithspreadingcellulitis.

Boneandjointinfections,inparticularosteomyelitis.

Considerationshouldbegiventoofficialguidanceontheappropriateuseofantibacterialagents.

4.2Posologyandmethodofadministration

Dosesareexpressedthroughoutintermsofamoxicillin/clavulanicacidcontentexceptwhendosesarestatedinterms

ofanindividualcomponent.

ThedoseofAmoxicillin/ClavulanicacidPfizerthatisselectedtotreatanindividualinfectionshouldtakeintoaccount:

Theexpectedpathogensandtheirlikelysusceptibilitytoantibacterialagents(seesection4.4)

Theseverityandthesiteoftheinfection

Theage,weightandrenalfunctionofthepatientasshownbelow.

Theuseofalternativepresentationsofamoxicillin/clavulanicacid(e.g.thosethatprovidehigherdosesofamoxicillin

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 29/08/2011 CRN 2093373 page number: 1

Foradultsandchildren 40kg,thisformulationofAmoxicillin/ClavulanicacidPfizerprovidesatotaldailydoseof

1750mgamoxicillin/250mgclavulanicacidwithtwicedailydosingand2625mgamoxicillin/375mgclavulanicacid

withthreetimesdailydosing,whenadministeredasrecommendedbelow.Forchildren<40kg,thisformulationof

Amoxicillin/ClavulanicacidPfizerprovidesamaximumdailydoseof1000-2800mgamoxicillin/143-400mg

clavulanicacid,whenadministeredasrecommendedbelow.Ifitisconsideredthatahigherdailydoseofamoxicillinis

required,itisrecommendedthatanotherpreparationofamoxicillin/clavulanicacidisselectedinordertoavoid

administrationofunnecessarilyhighdailydosesofclavulanicacid(seesections4.4and5.1).

Thedurationoftherapyshouldbedeterminedbytheresponseofthepatient.Someinfections(e.g.osteomyelitis)

requirelongerperiodsoftreatment.Treatmentshouldnotbeextendedbeyond14dayswithoutreview(seesection4.4

regardingprolongedtherapy).

Adultsandchildren 40kg

Recommendeddoses:

Standarddose:(forallindications)875mg/125mgtwotimesaday.

Higherdose–(particularlyforinfectionssuchasotitismedia,sinusitis,lowerrespiratorytract

infectionsandurinarytractinfections):875mg/125mgthreetimesaday.

Children<40kg

Recommendeddoses:

25mg/3.6mg/kg/dayto45mg/6.4mg/kg/daygivenastwodivideddoses.

Upto70mg/10mg/kg/daygivenastwodivideddosesmaybeconsideredforsomeinfections(such

asotitismedia,sinusitisandlowerrespiratorytractinfections).

Noclinicaldataareavailableforamoxicillin/clavulanicacid7:1formulationsregardingdoseshigherthan45mg/

6.4mg/kgperdayinchildrenunder2years.

Therearenoclinicaldataforamoxicillin/clavulanicacid7:1formulationsforpatientsunder2monthsofage.Dosing

recommendationsinthispopulationthereforecannotbemade.

Elderly

Nodoseadjustmentisconsiderednecessary.

Renalimpairment

Nodoseadjustmentisrequiredinpatientswithcreatinineclearance(CrCl)greaterthan30ml/min.

Inpatientswithcreatinineclearancelessthan30ml/min,theuseofamoxicillin/clavulanicacidpresentationswith

amoxicillintoclavulanicacidratioof7:1isnotrecommended,asnorecommendationsfordoseadjustmentsare

available.

Hepaticimpairment

Dosewithcautionandmonitorhepaticfunctionatregularintervals(seesections4.3and4.4).

Methodofadministration

Amoxicillin/ClavulanicacidPfizerisfororaluse.

Administeratthestartofamealtominimisepotentialgastrointestinalintoleranceandoptimiseabsorptionof

amoxicillin/clavulanicacid.

4.3Contraindications

Hypersensitivitytotheactivesubstances,toanyofthepenicillinsortoanyoftheexcipients.

Historyofasevereimmediatehypersensitivityreaction(e.g.anaphylaxis)toanotherbeta-lactamagent(e.g.

cephalosporin,carbapenemormonobactam).

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 29/08/2011 CRN 2093373 page number: 2

4.4Specialwarningsandprecautionsforuse

Beforeinitiatingtherapywithamoxicillin/clavulanicacid,carefulenquiryshouldbemadeconcerningprevious

hypersensitivityreactionstopenicillins,cephalosporinsorotherbeta-lactamagents(seesections4.3and4.8).

Seriousandoccasionallyfatalhypersensitivity(anaphylactoid)reactionshavebeenreportedinpatientsonpenicillin

therapy.Thesereactionsaremorelikelytooccurinindividualswithahistoryofpenicillinhypersensitivityandin

atopicindividuals.Ifanallergicreactionoccurs,amoxicillin/clavulanicacidtherapymustbediscontinuedand

appropriatealternativetherapyinstituted.

Inthecasethataninfectionisproventobeduetoanamoxicillin-susceptibleorganism(s)thenconsiderationshouldbe

giventoswitchingfromamoxicillin/clavulanicacidtoamoxicillininaccordancewithofficialguidance.

ThispresentationofCo-amoxiclavPfizerisnotsuitableforusewhenthereisahighriskthatthepresumptive

pathogenshavereducedsusceptibilityorresistancetobeta-lactamagentsthatisnotmediatedbybeta-lactamases

susceptibletoinhibitionbyclavulanicacid.Thispresentationshouldnotbeusedtotreatpenicillin-resistantS.

pneumoniae.

Convulsionsmayoccurinpatientswithimpairedrenalfunctionorinthosereceivinghighdoses(seesections4.8).

Amoxicillin/Clavulanicacidshouldbeavoidedifinfectiousmononucleosisissuspectedsincetheoccurrenceofa

morbilliformrashhasbeenassociatedwiththisconditionfollowingtheuseofamoxicillin.

Concomitantuseofallopurinolduringtreatmentwithamoxicillinamoxicillincanincreasethelikelihoodofallergic

skinreactions.

Prolongedusemayoccasionallyresultinovergrowthofnon-susceptibleorganisms.

Theoccurrenceatthetreatmentinitiationofafeverishgeneralisederythemaassociatedwithpustulamaybeasymptom

ofacutegeneralisedexanthemouspustulosis(AGEP)(seesection4.8).ThisreactionrequiresCo-amoxiclavPfizer

discontinuationandcontra-indicatesanysubsequentadministrationofamoxicillin.

Amoxicillin/Clavulanicacidshouldbeusedwithcautioninpatientswithevidenceofhepaticimpairment(seesections

4.2,4.3and4.8).

Hepaticeventshavebeenreportedpredominantlyinmalesandelderlypatientsandmaybeassociatedwithprolonged

treatment.Theseeventshavebeenveryrarelyreportedinchildren.Inallpopulations,signsandsymptomsusually

occurduringorshortlyaftertreatmentbutinsomecasesmaynotbecomeapparentuntilseveralweeksaftertreatment

hasceased.Theseareusuallyreversible.Hepaticeventsmaybesevereand,inextremelyrarecircumstances,deaths

havebeenreported.Thesehavealmostalwaysoccurredinpatientswithseriousunderlyingdiseaseortaking

concomitantmedicationsknowntohavethepotentialforhepaticeffects(seesection4.8).

Antibiotic-associatedcolitishasbeenreportedwithnearlyallantibacterialagentsincludingamoxicillinandmayrange

inseverityfrommildtolifethreatening(seesection4.8).Therefore,itisimportanttoconsiderthisdiagnosisinpatients

whopresentwithdiarrhoeaduringorsubsequenttotheadministrationofanyantibiotics.Should-antibioticassociated

colitisoccur,Co-amoxiclavPfizershouldimmediatelybediscontinued,aphysicianbeconsultedandanappropriate

therapyinitiated.Anti-peristalticmedicinalproductsarecontra-indicatedinthissituation.

Periodicassessmentoforgansystemfunctions,includingrenal,hepaticandhaematopoieticfunctionisadvisableduring

prolongedtherapy.

Prolongationofprothrombintimehasbeenreportedrarelyinpatientsreceivingamoxicillin/clavulanicacid.

Appropriatemonitoringshouldbeundertakenwhenanticoagulantsareprescribedconcomitantly.Adjustmentsinthe

doseoforalanticoagulantsmaybenecessarytomaintainthedesiredlevelofanticoagulation(seesection4.5and4.8).

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 29/08/2011 CRN 2093373 page number: 3

Inpatientswithreducedurineoutput,crystalluriahasbeenobservedveryrarely,predominantlywithparenteral

therapy.Duringtheadministrationofhighdosesofamoxicillin,itisadvisabletomaintainadequatefluidintakeand

urinaryoutputinordertoreducethepossibilityofamoxicillincrystalluria.Inpatientswithbladdercatheters,aregular

checkofpatencyshouldbemaintained(seesection4.9).

Duringtreatmentwithamoxicillin,enzymaticglucoseoxidasemethodsshouldbeusedwhenevertestingforthe

presenceofglucoseinurinebecausefalsepositiveresultsmayoccurwithnon-enzymaticmethods.

ThepresenceofclavulanicacidinCo-amoxiclavPfizermaycauseanon-specificbindingofIgGandalbuminbyred

cellmembranesleadingtoafalsepositiveCoombstest.

TherehavebeenreportsofpositivetestresultsusingtheBio-RadLaboratoriesPlateliaAspergillusEIAtestinpatients

receivingamoxicillin/clavulanicacidwhoweresubsequentlyfoundtobefreeofAspergillusinfection.Cross-reactions

withnon-AspergilluspolysaccharidesandpolyfuranoseswithBio-RadLaboratoriesPlateliaAspergillusEIAtesthave

beenreported.Therefore,positivetestresultsinpatientsreceivingamoxicillin/clavulanicacidshouldbeinterpreted

cautiouslyandconfirmedbyotherdiagnosticmethods.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

Oralanticoagulants

Oralanticoagulantsandpenicillinantibioticshavebeenwidelyusedinpracticewithoutreportsofinteraction.

However,intheliteraturetherearecasesofincreasedinternationalnormalisedratioinpatientsmaintainedon

acenocoumarolorwarfarinandprescribedacourseofamoxicillin.Ifco-administrationisnecessary,theprothrombin

timeorinternationalnormalisedratioshouldbecarefullymonitoredwiththeadditionorwithdrawalofamoxicillin.

Moreover,adjustmentsinthedoseoforalanticoagulantsmaybenecessary(seesections4.4and4.8).

Methotrexate

Penicillinsmayreducetheexcretionofmethotrexatecausingapotentialincreaseintoxicity.

Probenecid

Concomitantuseofprobenecidisnotrecommended.Probeneciddecreasestherenaltubularsecretionofamoxicillin.

Concomitantuseofprobencidmayresultinincreasedandprolongedbloodlevelsofamoxicillinbutnotofclavulanic

acid.

4.6Fertility,pregnancyandlactation

Pregnancy

Animalstudiesdonotindicatedirectorindirectharmfuleffectswithrespecttopregnancy,embryonal/foetal

development,parturitionorpostnataldevelopment(seesection5.3).Limiteddataontheuseofamoxicillin/clavulanic

acidduringpregnancyinhumansdonotindicateanincreasedriskofcongenitalmalformations.Inasinglestudyin

womenwithpreterm,prematureruptureofthefoetalmembraneitwasreportedthatprophylactictreatmentwith

amoxicillin/clavulanicacidmaybeassociatedwithanincreasedriskofnecrotisingenterocolitisinneonates.Use

shouldbeavoidedduringpregnancy,unlessconsideredessentialbythephysician.

Lactation

Bothsubstancesareexcretedintobreastmilk(nothingisknownoftheeffectsofclavulanicacidonthebreast-fed

infant).Consequently,diarrhoeaandfungusinfectionofthemucousmembranesarepossibleinthebreast-fedinfant,so

thatbreast-feedingmighthavetobediscontinued.

Amoxicillin/clavulanicacidshouldonlybeusedduringbreast-feedingafterbenefit/riskassessmentbythephysicianin

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 29/08/2011 CRN 2093373 page number: 4

4.7Effectsonabilitytodriveandusemachines

Nostudiesontheeffectsontheabilitytodriveandusemachineshavebeenperformed.However,undesirableeffects

mayoccur(e.g.allergicreactions,dizziness,convulsions),whichmayinfluencetheabilitytodriveandusemachines

(seesection4.8).

4.8Undesirableeffects

Themostcommonlyreportedadversedrugreactions(ADRs)arediarrhoea,nauseaandvomiting.

TheADRsderivedfromclinicalstudiesandpost-marketingsurveillancewithamoxicillin/clavulanicacid,sortedby

MedDRASystemOrganClassarelistedbelow.

Thefollowingterminologieshavebeenusedinordertoclassifytheoccurrenceofundesirableeffects.

Verycommon(1/10)

Common(1/100to<1/10)

Uncommon(1/1,000to<1/100)

Rare(1/10,000to<1/1,000)

Veryrare(<1/10,000)

Notknown(cannotbeestimatedfromtheavailabledata)

Infectionsandinfestations

Mucocutaneouscandidosis Common

Overgrowthofnon-susceptible

organisms Notknown

Bloodandlymphaticsystemdisorders

Reversibleleucopenia(including

neutropenia) Rare

Thrombocytopenia Rare

Reversibleagranulocytosis Notknown

Haemolyticanaemia Notknown

Prolongationofbleedingtimeand

prothrombintime 1 Notknown

Immunesystemdisorders 10

Angioneuroticoedema Notknown

Anaphylaxis Notknown

Serumsickness-likesyndrome Notknown

Hypersensitivityvasculitis Notknown

Nervoussystemdisorders

Dizziness Uncommon

Headache Uncommon

Reversiblehyperactivity Notknown

Convulsions 2 Notknown

Gastrointestinaldisorders

Diarrhoea Verycommon

Nausea 3 Common

Vomiting Common

Indigestion Uncommon

Antibiotic-associatedcolitis 4 Notknown

Blackhairytongue Notknown

Hepatobiliarydisorders

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 29/08/2011 CRN 2093373 page number: 5

4.9Overdose

Symptomsandsignsofoverdose

Gastrointestinalsymptomsanddisturbanceofthefluidandelectrolytebalancesmaybeevident.Amoxicillin

crystalluria,insomecasesleadingtorenalfailure,hasbeenobserved(seesection4.4).

Convulsionsmayoccurinpatientswithimpairedrenalfunctionorinthosereceivinghighdoses.

Amoxicillinhasbeenreportedtoprecipitateinbladdercatheters,predominantlyafterintravenousadministrationof

largedoses.Aregularcheckofpatencyshouldbemaintained(seesection4.4).

Treatmentofintoxication

Gastrointestinalsymptomsmaybetreatedsymptomatically,withattentiontothewater/electrolytebalance.

Hepatitis 6 Notknown

Cholestaticjaundice 6 Notknown

Skinandsubcutaneoustissuedisorders 7

Skinrash Uncommon

Pruritus Uncommon

Urticaria Uncommon

Erythemamultiforme Rare

Stevens-Johnsonsyndrome Notknown

Toxicepidermalnecrolysis Notknown

Bullousexfoliative-dermatitis Notknown

Acutegeneralizedexanthemous

pustulosis(AGEP) 9 Notknown

Renalandurinarydisorders

Interstitialnephritis Notknown

Crystalluria 8 Notknown

Seesection4.4

Seesection4.4

Nauseaismoreoftenassociatedwithhigheroraldoses.Ifgastrointestinal

reactionsareevident,theymaybereducedbytakingamoxicillin/clavulanicacidat

thestartofameal

Includingpseudomembranouscolitisandhaemorrhagiccolitis(seesection4.4)

AmoderateriseinASTand/orALThasbeennotedinpatientstreatedwithbeta-

lactamclassantibiotics,butthesignificanceofthesefindingsisunknown.

Theseeventshavebeennotedwithotherpenicillinsandcephalosporins(see

section4.4).

Ifanyhypersensitivitydermatitisreactionoccurs,treatmentshouldbe

discontinued(seesection4.4)

Seesection4.9

Seesection4.4

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 29/08/2011 CRN 2093373 page number: 6

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

Pharmacotherapeuticgroup:Combinationsofpenicillins,incl.beta-lactamaseinhibitors;ATCcodeJ01CR02.

Modeofaction

Amoxicillinisasemisyntheticpenicillin(beta-lactamantibiotic)thatinhibitsoneormoreenzymes(oftenreferredtoas

penicillin-bindingproteins,PBPs)inthebiosyntheticpathwayofbacterialpeptidoglycan,whichisanintegralstructural

componentofthebacterialcellwall.Inhibitionofpeptidoglycansynthesisleadstoweakeningofthecellwall,whichis

usuallyfollowedbycelllysisanddeath.

Amoxicillinissusceptibletodegradationbybeta-lactamasesproducedbyresistantbacteriaandthereforethespectrum

ofactivityofamoxicillinalonedoesnotincludeorganismswhichproducetheseenzymes.

Clavulanicacidisabeta-lactamstructurallyrelatedtopenicillins.Itinactivatessomebeta-lactamaseenzymesthereby

preventinginactivationofamoxicillin.Clavulanicacidalonedoesnotexertaclinicallyusefulantibacterialeffect.

PK/PDrelationship

Thetimeabovetheminimuminhibitoryconcentration(T>MIC)isconsideredtobethemajordeterminantofefficacy

foramoxicillin.

Mechanismsofresistance

Thetwomainmechanismsofresistancetoamoxicillin/clavulanicacidare:

Inactivationbythosebacterialbeta-lactamasesthatarenotthemselvesinhibitedbyclavulanicacid,including

classB,CandD.

AlterationofPBP'swhichreducetheaffinityoftheantibacterialagentforthetarget.

Impermeabilityofbacteriaoreffluxpumpmechanismsmaycauseorcontributetobacterialresistance,particularlyin

Gram-negativebacteria.

Breakpoints

MICbreakpointsforamoxicillin/clavulanicacidarethoseoftheEuropeanCommitteeonAntimicrobialSusceptibility

Testing(EUCAST)

Organism SusceptibilityBreakpoints(µg/ml)

Susceptible Intermediate Resistant

Haemophilus

influenzae 1 1 - >1

Moraxella

catarrhalis 1 1 - >1

Staphylococcus

aureus 2 2 - >2

Coagulase-negative

staphylococci 2 0.25 >0.25

Enterococcus 1 4 8 >8

StreptococcusA,B,

C,G 5 0.25 - >0.25

Streptococcus

pneumoniae 3 0.5 1-2 >2

Enterobacteriaceae 1,4 - - >8

Gram-negative

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 29/08/2011 CRN 2093373 page number: 7

Theprevalenceofresistancemayvarygeographicallyandwithtimeforselectedspecies,andlocalinformationon

resistanceisdesirable,particularlywhentreatingsevereinfections.Asnecessary,expertadviceshouldbesoughtwhen

Gram-positive

Anaerobes 1 4 8 >8

Non-speciesrelated

breakpoints 1 2 4-8 >8

ThereportedvaluesareforAmoxicillinconcentrations.

Forsusceptibilitytestingpurposes,theconcentrationof

Clavulanicacidisfixedat2mg/l.

ThereportedvaluesareOxacillinconcentrations.

BreakpointvaluesinthetablearebasedonAmpicillin

breakpoints.

TheresistantbreakpointofR>8mg/lensuresthatall

isolateswithresistancemechanismsarereportedresistant.

Breakpointvaluesinthetablearebasedon

Benzylpenicillinbreakpoints.

Commonlysusceptiblespecies

AerobicGram-positivemicro-organisms

Enterococcusfaecalis

Gardnerellavaginalis

Staphylococcusaureus(methicillin-susceptible)£

Coagulase-negativestaphylococci(methicillin-susceptible)

Streptococcusagalactiae

Streptococcuspneumoniae 1

Streptococcuspyogenesandotherbeta-haemolyticstreptococci

Streptococcusviridansgroup

AerobicGram-negativemicro-organisms

Capnocytophagaspp.

Eikenellacorrodens

Haemophilusinfluenzae 2

Moraxellacatarrhalis

Pasteurellamultocida

Anaerobicmicro-organisms

Bacteroidesfragilis

Fusobacteriumnucleatum

Prevotellaspp.

Speciesforwhichacquiredresistancemaybeaproblem

AerobicGram-positivemicro-organisms

Enterococcusfaecium$

AerobicGram-negativemicro-organisms

Escherichiacoli

Klebsiellaoxytoca

Klebsiellapneumoniae

Proteusmirabilis

Proteusvulgaris

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 29/08/2011 CRN 2093373 page number: 8

5.2Pharmacokineticproperties

Absorption

Amoxicillinandclavulanicacid,arefullydissociatedinaqueoussolutionatphysiologicalpH.Bothcomponentsare

rapidlyandwellabsorbedbytheoralrouteofadministration.Absorptionofamoxicillin/clavulanicacidisoptimised

whentakenatthestartofameal.Followingoraladministration,amoxicillinandclavulanicacidareapproximately

70%bioavailable.Theplasmaprofilesofbothcomponentsaresimilarandthetimetopeakplasmaconcentration

)ineachcaseisapproximatelyonehour.

Thepharmacokineticresultsforastudy,inwhichamoxicillin/clavulanicacid(875mg/125mgtabletsgiventwice

daily)wasadministeredinthefastingstatetogroupsofhealthyvolunteersarepresentedbelow.

Amoxicillinandclavulanicacidserumconcentrationsachievedwithamoxicillin/clavulanicacidaresimilartothose

producedbytheoraladministrationofequivalentdosesofamoxicillinorclavulanicacidalone.

Distribution

About25%oftotalplasmaclavulanicacidand18%oftotalplasmaamoxicillinisboundtoprotein.Theapparent

AerobicGram-negativemicro-organisms

Acinetobactersp.

Citrobacterfreundii

Enterobactersp.

Legionellapneumophila

Morganellamorganii

Providenciaspp.

Pseudomonassp.

Serratiasp.

Stenotrophomonasmaltophilia

Othermicro-organisms

Chlamydophilapneumoniae

Chlamydophilapsittaci

Coxiellaburnetti

Mycoplasmapneumoniae

$Naturalintermediatesusceptibilityintheabsenceofacquiredmechanismofresistance.

£Allmethicillin-resistantstaphylococciareresistanttoamoxicillin/clavulanicacid

Streptococcuspneumoniaethatareresistanttopenicillinshouldnotbetreatedwiththispresentationof

amoxicillin/clavulanicacid(seesections4.2and4.4).

StrainswithdecreasedsusceptibilityhavebeenreportedinsomecountriesintheEUwithafrequency

higherthan10%.

Mean(±SD)pharmacokineticparameters

Activesubstance(s)

administered Dose C

(0-24h) T1/2

(mg) (µg/ml) (h) (µg.h/ml) (h)

Amoxicillin

AMX/CA875/125mg 875 11.64±2.78 1.50(1.0-2.5) 53.52±12.31 1.19±0.21

Clavulanicacid

AMX/CA875/125mg 125 2.18±0.99 1.25(1.0-2.0) 10.16±3.04 0.96±0.12

AMX-amoxicillin,CA-clavulanicacid

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 29/08/2011 CRN 2093373 page number: 9

Followingintravenousadministration,bothamoxicillinandclavulanicacidhavebeenfoundingallbladder,abdominal

tissue,skin,fat,muscletissues,synovialandperitonealfluids,bileandpus.Amoxicillindoesnotadequatelydistribute

intothecerebrospinalfluid.

Fromanimalstudiesthereisnoevidenceforsignificanttissueretentionofdrugderivedmaterialforeithercomponent.

Amoxicillin,likemostpenicillins,canbedetectedinbreastmilk.Tracequantitiesofclavulanicacidcanalsobe

detectedinbreastmilk(seesection4.6).

Bothamoxicillinandclavulanicacidhavebeenshowntocrosstheplacentalbarrier(seesection4.6).

Biotransformation

Amoxicillinispartlyexcretedintheurineastheinactivepenicilloicacidinquantitiesequivalenttoupto10to25%of

theinitialdose.Clavulanicacidisextensivelymetabolizedinmanandeliminatedinurineandfaecesandascarbon

dioxideinexpiredair.

Elimination

Themajorrouteofeliminationforamoxicillinisviathekidney,whereasforclavulanicaciditisbybothrenalandnon-

renalmechanisms.

Amoxicillin/clavulanicacidhasameaneliminationhalf-lifeofapproximatelyonehourandameantotalclearanceof

approximately25l/hinhealthysubjects.Approximately60to70%oftheamoxicillinandapproximately40to65%of

theclavulanicacidareexcretedunchangedinurineduringthefirst6hafteradministrationofsingle

amoxicillin/Clavulanicacid250mg/125mgor500mg/125mgtablets.Variousstudieshavefoundtheurinaryexcretion

tobe50-85%foramoxicillinandbetween27-60%forclavulanicacidovera24hourperiod.Inthecaseofclavulanic

acid,thelargestamountofdrugisexcretedduringthefirst2hoursafteradministration.

Concomitantuseofprobeneciddelaysamoxicillinexcretionbutdoesnotdelayrenalexcretionofclavulanicacid(see

section4.5).

Theeliminationhalf-lifeofamoxicillinissimilarforchildrenagedaround3monthsto2yearsandolderchildrenand

adults.Forveryyoungchildren(includingpretermnewborns)inthefirstweekoflifetheintervalofadministration

shouldnotexceedtwicedailyadministrationduetoimmaturityoftherenalpathwayofelimination.Becauseelderly

patientsaremorelikelytohavedecreasedrenalfunction,careshouldbetakenindoseselection,anditmaybeusefulto

monitorrenalfunction.

Gender

Followingoraladministrationofamoxicillin/clavulanicacidtohealthymalesandfemalesubjects,genderhasno

significantimpactonthepharmacokineticsofeitheramoxicillinorclavulanicacid.

Renalimpairment

Thetotalserumclearanceofamoxicillin/clavulanicaciddecreasesproportionatelywithdecreasingrenalfunction.The

reductionindrugclearanceismorepronouncedforamoxicillinthanforclavulanicacid,asahigherproportionof

amoxicillinisexcretedviatherenalroute.Dosesinrenalimpairmentmustthereforepreventundueaccumulationof

amoxicillinwhilemaintainingadequatelevelsofclavulanicacid(seesection4.2).

Hepaticimpairment

Hepaticallyimpairedpatientsshouldbedosedwithcautionandhepaticfunctionmonitoredatregularintervals.

5.3Preclinicalsafetydata

Nonclinicaldatarevealnospecialhazardforhumansbasedonstudiesofsafetypharmacology,genotoxicityand

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 29/08/2011 CRN 2093373 page number: 10

Repeatdosetoxicitystudiesperformedindogswithamoxicillin/clavulanicaciddemonstrategastricirritancyand

vomiting,anddiscolouredtongue.

Carcinogenicitystudieshavenotbeenconductedwithamoxicillin/clavulanicacidoritscomponents.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Core:

Microcrystallinecellulose(E460)

Colloidalanhydroussilica

Magnesiumstearate(E470b)

Sodiumstarchglycolate(TypeA)

Filmcoating

Hypromellose(E464)

Macrogol400

Titaniumdioxide(E171)

6.2Incompatibilities

Notapplicable

6.3Shelflife

2years

6.4Specialprecautionsforstorage

Storeintheoriginalpackageinordertoprotectfromlightandmoisture.

6.5Natureandcontentsofcontainer

ThetabletsarepackedinAlu/Alu(polyamide/aluminium/PVC-aluminiumfoil)blisterpacksinacardboardbox.

Co-amoxiclavPfizertabletsareavailableinblisterpackswith4,5,6,7,8,10,12,14,15,16,20,21,25,30,35,40,50,

100and500film-coatedtablets.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsfordisposal

Anyunusedproductorwastematerialshouldbedisposedofinaccordancewithlocalrequirements.

7MARKETINGAUTHORISATIONHOLDER

PfizerHealthcareIreland

9Riverwalk

NationalDigitalPark

CitywestBusinessCampus

Dublin24

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 29/08/2011 CRN 2093373 page number: 11

8MARKETINGAUTHORISATIONNUMBER

PA822/85/2

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation:26August2011

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 29/08/2011 CRN 2093373 page number: 12